← All trials
NCT02538471
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2015
- Primary completion
- Sep 4, 2018
- Completion date
- Feb 20, 2019
- First posted
- Sep 2, 2015
- Last posted
- Dec 9, 2019
- Enrollment
- 3
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cornell UniversityLead sponsor
- Cornell UniversityOverall official - principal investigator
- University of California, Los AngelesCollaborator
- Cornell UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.